FX-909, the first small molecule targeting PPARG to be tested in humans, showed monotherapy activity in advanced urothelial ...
FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma ...
EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds through analysis of U.S. longitudinal ...
T3D-959, an oral dual delta/gamma peroxisome proliferator-activated nuclear receptor (PPAR) agonist, has shown promise in a phase 2 randomized, placebo-controlled study of adults with mild-to-moderate ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting I. This abstract does not include a full text component.
Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover ...
Correlative analyses between EGFR pathways and stroma-tumor profiles in head and neck cancer patients (HNSCC) on postoperative radiotherapy plus cisplatin (PORTc) plus or minus gefitinib ...
Annals of Nutrition & Metabolism, Vol. 75, No. 3 (2019), p. 197 (1 page) Liang J, Lan J, Li M, Wang F. Associations of Leptin Receptor and Peroxisome Proliferator-Activated Receptor Gamma ...
The European Medicines Agency (EMA) has swatted away Minoryx Therapeutics’ attempt to bring a rare disease drug candidate to market on the strength of a clinical trial that missed its primary endpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback